Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies

By Ciccarelli Giovanni   D’Elia Saverio   De Paulis Michele   Golino Paolo   Cimmino Giovanni  

Diseases, Vol. 6, Iss. 1, 2018-03 ,pp. : 22-22

MDPI

Access to resources Recommend Favorite

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway

By Xu Weiming   Liu Lizhi   Hornby David  

Molecules, Vol. 17, Iss. 10, 2012-10 ,pp. : 12086-12101

MDPI

Access to resources Recommend Favorite

Discovery of Flavonoids from Scutellaria baicalensis with Inhibitory Activity Against PCSK 9 Expression: Isolation, Synthesis and Their Biological Evaluation

By Nhoek Piseth   Chae Hee-Sung   Masagalli Jagadeesh Nagarajappa   Mailar Karabasappa   Pel Pisey   Kim Young-Mi   Choi Won Jun   Chin Young-Won  

Molecules, Vol. 23, Iss. 2, 2018-02 ,pp. : 504-504

MDPI

Access to resources Recommend Favorite

Non-Native Conformational Isomers of the Catalytic Domain of PCSK9 Induce an Immune Response, Reduce Lipids and Increase LDL Receptor Levels

By Jiang Chuantao   Nischal Hersharan   Sun Hua   Li Li   Cao Ying   Wei Peng   Chang Jui-Yoa   Teng Ba-Bie  

International Journal of Molecular Sciences, Vol. 19, Iss. 2, 2018-02 ,pp. : 640-640

MDPI

Access to resources Recommend Favorite

Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives ^†

By Hussack Greg   Tanha Jamshid  

Toxins, Vol. 2, Iss. 5, 2010-05 ,pp. : 998-1018

MDPI

Access to resources Recommend Favorite